佩罗尼病的当代非手术治疗方法
Alexandr M Pinkhasov1, David Y Yang2, Elise Tentis1
1Mayo Clinic - Rochester Minnesota.
Current opinion in urology
|January 2, 2025
概括
皮罗尼病的非手术治疗方法,包括阴茎引和原酶Clostridium histolyticum (CCH) 注射,显示出有前途. 口服治疗缺乏强有力的证据,而维拉帕米尔和干扰素α-2b具有混合或有限的结果.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 安德罗学与人类学
- 医学治疗学 医学治疗学
背景情况:
- 皮罗尼氏病涉及阴茎曲,通常没有自发的解决方案.
- 患者通过手术或非手术干预来寻求治疗.
- 当代非手术选择是本文的重点.
研究的目的:
- 审查目前对皮罗尼病的非手术治疗策略.
- 评估各种非手术治疗的疗效和支持证据.
主要方法:
- 审查当代非手术治疗方案.
- 对口服治疗,损伤内注射和阴茎引疗法的证据分析.
- 考虑随机对照试验和专家协会的建议.
主要成果:
- 口服治疗缺乏高水平的疗效证据.
- 阴茎引疗法,特别是第二代设备,显示出强大的疗效.
- 内损伤原酶Clostridium histolyticum (CCH) 从IMPRESS试验中获得了强有力的证据.
- 维拉帕米尔显示不一致的疗效证据.
- 干扰素α-2b提供了适度的改善,但在北美没有.
结论:
- 皮罗尼病的非手术治疗方法已经进步.
- 阴茎伸缩和CCH注射是主要的非手术选择.
- 进一步的研究可能会澄清其他药物的作用,如维拉帕米尔.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
129
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
129
Peptic Ulcer Disease IV: Management
72
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
72
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
Peptic Ulcer Disease V: Surgical Management and Nursing Care
224
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
224
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
135
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
135
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
133
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
133


